Resveratrol successfully treats experimental endometriosis through modulation of oxidative stress and lipid peroxidation

Abstract

In a rat endometriosis model, resveratrol showed potential ameliorative effects on endometriotic implants probably due to its potent antioxidative properties.

Targeting oxidative stress to treat endometriosis

“…In continuation to the positive reported effect of resveratrol on endometriosis [101], similar encouraging results of reduction in endometrial lesions size, cell proliferation, vascularization, inflammation, OS and lipid peroxidation markers were recently reported in several animal studies [102][103][104][105][106].…”

“…Reduction of proliferation of endometrial cells (through inhibition of AKT and MAPK1/3), increased apoptosis, and reduced ability of the endometrial tissue to attach and to implant Yavuz S et al [104] Animal study Reduction of endometriotic implant volumes, proliferating cell nuclear antigen expression levels, increase in activities of superoxide dismutase and glutathione peroxidase in serum and tissue…”

Chronic Niche Inflammation in Endometriosis-Associated Infertility: Current Understanding and Future Therapeutic Strategies

“…Resveratrol is a polyphenolic compound isolated from plants and has been demonstrated to reduce inflammation and oxidative stress in preclinical endometriosis models [125,126]. Epigallocatechin gallate (EGCg) is a green tea extract that exerts immunomodulation activities via increased peritoneal phagocytic activity and NK cell cytolysis [127].…”

Treatment of Endometriosis with Non-Hormonal Agents: Review

“…30 Yavuz ve ark., endometriyozisli sıçanlarda resveratrol kullandıkları çalışmada, resveratrol kullanılan grupta, kontrol grubuna göre endometriyotik doku hacminde, serum ve dokuda süperoksit dismutaz ve glutatyon peroksidaz enzim düzeylerinde istatistiksel olarak anlamlı azalma, malonil dialdehid dü-zeyinde ise istatistiksel olarak anlamlı artış saptamışlardır. 31 Ricci, endometriyozis oluşturulan sıçanlarda resveratrol ve epigallocatekin-3 gallate (EGCG) kullanımı sonrası endometriyotik lezyonların hacimlerinde, hücre proliferasyonunda ve mikrovasküler yapıların yoğunluğunda istatistiksel olarak anlamlı azalma, apoptoziste ise artma olduğunu bildirmiştir. 32 EGCG, endometriyotik lezyonda, VEGF-C ve VEGF-2 reseptörü tirozin kinazın oluşumunu azaltarak mikrovasküler yapı-ların oluşumunu inhibe ederler.…”